Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1543091 | 1.00 | LMNA (0.35) | LMNACES2 | |
| SCHEMBL385341 | 1.00 | LMNA (0.35) | LMNACES2 | |
| Hydrochloric Acid SCHEMBL3309454 | 0.97 | LMNA (0.34) | LMNACES2 | |
| Hydrochloric Acid SCHEMBL3309450 | 0.97 | LMNA (0.34) | LMNACES2 | |
| Hydrochloric Acid SCHEMBL26087108 | 0.97 | LMNA (0.34) | LMNACES2 | |
| Acetic Acid SCHEMBL5090221 | 0.89 | CES2 (0.38) | LMNACES2 | |
| SCHEMBL456619 | 0.85 | — | — | |
| SCHEMBL7526154 | 0.85 | LMNA (0.42) | LMNACES2 | |
| SCHEMBL1543559 | 0.84 | LMNA (0.33) | LMNACES2 | |
| SCHEMBL14639220 | 0.84 | LMNA (0.33) | LMNACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2021-08-05 | — | — | US | claimed |
| EP-1628968-B1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-04-06 | — | — | EP | claimed |
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4702026-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-4169575-B1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMA (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4606433-A2 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | Sumitomo Pharma America, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250195518-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2025-06-19 | — | — | US | disclosed |
| EP-3924351-B1 | CRYSTALLINE FORM OF THE HYDROCHLORIDE SALT OF 2-((1R,4R)-4-((3-(3-(TRIFLUOROMETHYL)PHENYL) IMIDAZO[1,2-B]PYRIDAZIN-6-YL)AMINO)CYCLOHEXYL)PROPAN-2-OL | SUMITOMO PHARMA AMERICA INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250074906-A1 | AZAINDOLE DERIVATIVE THAT INHIBITS H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-06 | — | — | US | disclosed |
| EP-2112151-A2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2009-10-28 | — | — | EP | disclosed |
| CN-101478972-A | Haloaryl substituted aminopurines, compositions thereof, and methods of using same in therapy | SIGNAL PHARM LLC (US) | 2009-07-08 | — | — | CN | disclosed |
| EP-1838710-B1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1838710-B1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-7521446-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2009-04-21 | — | — | US | disclosed |
| CN-101142215-A | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARM LLC (US) | 2008-03-12 | — | — | CN | disclosed |
| US-20080021048-A1 | Methods of treatment and prevention using haloaryl substituted aminopurines | SIGNAL PHARMACEUTICALS, LLC | 2008-01-24 | — | — | US | disclosed |
| US-20070060598-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20060287344-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | PHARMACOPEIA, LLC | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | CD38, BCL9, BCL6B | LMNA 2079/4885CES2 1212/4885 |
| US-20060287344-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | TPMT, MGMT, HPRT1 | LMNA 974/4885CES2 4712/4885 |
| US-20250074906-A1 | AZAINDOLE DERIVATIVE THAT INHIBITS H-PGDS | HPGDS, PTGIS, HPGD | LMNA 2444/4885CES2 2718/4885 |
| US-20250195518-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | HPGDS, PTGIS, HPGD | LMNA 3276/4885CES2 2053/4885 |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | LMNA 2351/4885CES2 4399/4885 |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | LMNA 2351/4885CES2 4399/4885 |
| US-20080021048-A1 | Methods of treatment and prevention using haloaryl substituted aminopurines | TPMT, MGMT, SMAD3 | LMNA 961/4885CES2 4708/4885 |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | LMNA 2351/4885CES2 4399/4885 |
| US-20070060598-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | TPMT, MGMT, HPRT1 | LMNA 843/4885CES2 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.